Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET

Imaging Studies IV: Magnetic Resonance Imaging

Imaging Studies IV: Magnetic Resonance Imaging

Introduction:Magnetic Resonance Imaging, or MRI, can include a specialized imaging technique of the urinary system known as Magnetic Resonance Urography (MRU). This radiation-free technique uses strong magnetic fields and radio waves to produce detailed images with the help of a computer. MRU is particularly effective for visualizing fluid-filled structures like the kidneys, ureters, and bladder.Applications of MRI in the Genitourinary SystemKidneys and Ureters: MRI detects tumors, cysts,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

High Adoption, Higher Expectations: A Cross-Sectional Survey of Radiologist Engagement with Artificial Intelligence in the United Arab Emirates.

Journal of imaging informatics in medicine·2026

Same author

How Will PSMAddition Impact the Management of Prostate Cancer?

European urology focus·2026

Same author

Top advances of the year: Radiopharmaceutical therapy for prostate cancer.

Cancer·2026

Same author

PSMA-PET Total Tumor Volume Response: Ready for Prime Time or a Work in Progress?

European urology·2026

Same author

Temporal Trends in the Frequency of Concomitant Cancer and Cerebrovascular Disease Diagnoses in the United States.

Neurology. Clinical practice·2026

Same author

PET-guided Assessment of Amyloid Clearance and Outcomes in a Real-World Cohort of Patients with Alzheimer Disease undergoing Anti-Amyloid Therapy.

AJNR. American journal of neuroradiology·2026

Same journal

Ipsilateral sampling maintains clinically significant cancer detection and reduces overdiagnosis in PI-RADS 4-5 lesions.

Urologic oncology·2026

Same journal

Testis-sparing surgery for small testicular masses: Functional and oncological outcomes.

Urologic oncology·2026

Same journal

Subcapsular versus total orchiectomy in advanced prostate cancer: A systematic review and meta-analysis of clinical and patient-reported outcomes.

Urologic oncology·2026

Same journal

Featured SUO Fellow: Soum Lokeshwar, MD MBA.

Urologic oncology·2026

Same journal

Automating standardization of prostate cancer biopsy and histopathology reports with privacy-preserving local large language models.

Urologic oncology·2026

Same journal

Geospatial correlation of industrial plastics emissions with bladder and kidney cancer burden in Ohio.

Urologic oncology·2026

See all related articles

Search research articles

Related Experiment Video

Updated: May 21, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

Prostate-specific membrane antigen-based imaging.

Joseph R Osborne¹, Naveed H Akhtar, Shankar Vallabhajosula

¹Department of Radiology, Weill Cornell Medical College, New York, NY 10065, USA.

Urologic Oncology

|June 5, 2012

Summary

This summary is machine-generated.

Prostate cancer (CaP) imaging can be improved by targeting prostate-specific membrane antigen (PSMA). New agents, including antibodies and small molecules, show promise for more sensitive and specific CaP detection and management.

More Related Videos

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

Published on: March 21, 2025

Quantitation of Protein Expression and Co-localization Using Multiplexed Immuno-histochemical Staining and Multispectral Imaging

Quantitation of Protein Expression and Co-localization Using Multiplexed Immuno-histochemical Staining and Multispectral Imaging

Published on: April 8, 2016

Related Experiment Videos

Last Updated: May 21, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

Published on: March 21, 2025

Quantitation of Protein Expression and Co-localization Using Multiplexed Immuno-histochemical Staining and Multispectral Imaging

Quantitation of Protein Expression and Co-localization Using Multiplexed Immuno-histochemical Staining and Multispectral Imaging

Published on: April 8, 2016

Area of Science:

Oncology
Radiology
Molecular Imaging

Background:

Prostate cancer (CaP) is a common malignancy in North America.
Conventional imaging lacks specificity for CaP, limiting patient management.
Prostate-specific membrane antigen (PSMA) is overexpressed in CaP tissue.

Purpose of the Study:

To explore novel imaging agents targeting PSMA for improved CaP detection.
To evaluate the potential of antibodies and small molecules for PSMA-targeted imaging.

Main Methods:

Review of existing PSMA-targeting agents, including antibodies (e.g., Hu mAb J591) and small molecules (e.g., MIP-1072, MIP-1095).
Discussion of imaging characteristics, target binding, and potential for diagnostic applications using SPECT and PET.

Main Results:

Humanized monoclonal antibodies (Hu mAb J591) show potential but have limitations in imaging speed.
Small-molecule inhibitors (MIP-1072, MIP-1095) demonstrate high affinity for PSMA.
(123)I-MIP-1072 and (123)I-MIP-1095 successfully imaged CaP xenografts, indicating suitability for human trials.

Conclusions:

PSMA-targeted imaging agents, particularly small molecules, offer significant potential to enhance diagnostic sensitivity and specificity in prostate cancer.
Further development of these agents could revolutionize CaP imaging and patient management.